Open an account

Nemaura Medical

NMRD · OTC

$0.0001+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About NMRD

Nemaura Medical, Inc. operates as a holding company. The company is headquartered in Manhattan, New York and currently employs 36 full-time employees. The company went IPO on 2014-11-04. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and may also be used to screen pre-diabetic patients and support obesity and weight-loss programs. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The Company’s applications of its technology include glucose monitoring, temperature monitoring, lactate monitoring, alcohol monitoring, and substance abuse monitoring. Its platform uses precision microsystems-based technology.

Employees
36
Headquarters
Manhattan, New York
Listed
Nov 4, 2014
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
nemauramedical.com

NMRD key statistics

Market cap
4.04K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
510
Volume
975
Open price
$0.0001
High today
$0.0001
Low today
$0.0001
52 Week high
$0.05
52 Week low
$0.00

Nemaura Medical (NMRD) at a glance

Nemaura Medical (NMRD) last traded at $0.0001, with a market cap of 4.04K and a price-to-earnings ratio of 0.00.

Volume so far is 975 shares, above the average of 510 shares a day.

Over the past year Nemaura Medical has ranged from $0.00 to $0.05, and now sits 0% of the way up that range.

Nemaura Medical met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q3 FY24 it reported -$0.07 per share against an estimate of -$0.1224.

NMRD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 34.2% on average.

  1. Q4 FY22: reported -$0.15 per share against an estimate of -$0.1394
  2. Q1 FY23: reported -$0.17 per share against an estimate of -$0.1734
  3. Q2 FY23: reported -$0.17 per share against an estimate of -$0.1734
  4. Q3 FY23: reported -$0.07 per share against an estimate of -$0.1836
  5. Q4 FY23: reported -$0.18 per share against an estimate of -$0.1632
  6. Q1 FY24: reported -$0.09 per share against an estimate of -$0.153
  7. Q2 FY24: reported -$0.05 per share against an estimate of -$0.1122
  8. Q3 FY24: reported -$0.07 per share against an estimate of -$0.1224

Similar companies

Companies in the same industry as Nemaura Medical

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.